SABS icon

SAB Biotherapeutics
SABS

Overview Fund Activity

25 hedge funds and large institutions have $10.1M invested in SAB Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HWM
1
HB Wealth Management
Georgia
$982K
2
Geode Capital Management
2
Geode Capital Management
Massachusetts
$307K
3
Northern Trust
3
Northern Trust
Illinois
$43.2K
4
UBS Group
4
UBS Group
Switzerland
$4.11K
5
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.06M

Top Sellers

1
RI
1
RTW Investments
New York
$0
2
Millennium Management
2
Millennium Management
New York
$112K
3
First Manhattan
3
First Manhattan
New York
$0
4
Citadel Advisors
4
Citadel Advisors
Florida
$0
5
TRCT
5
Tower Research Capital (TRC)
New York
$3.2K
Name Holding Trade Value Shares
Change 		Shares
Change %
RI
26
RTW Investments
New York
– -$1.72M -635,276 Closed
First Manhattan
27
First Manhattan
New York
– -$66.4K -24,577 Closed
Citadel Advisors
28
Citadel Advisors
Florida
– -$27.8K -10,305 Closed
PGAM
29
Princeton Global Asset Management
New Jersey
– -$1.35K -500 Closed
1
2